Indian Influenza Market By Product Type (Vaxigrip, Influvac)-Forecast 2020

Published: Feb, 2017 | Pages: 90 | Publisher: RNCOS
Industry: Healthcare | Report Format: Electronic (PDF)

The Indian Influenza market has reported a remarkable growth in recent years, and is presenting ample opportunities to the industry's players. With increasing pandemic as well as seasonal outbreak and rising awareness among people about these vaccines, the Indian influenza vaccine market is poised to scale newer acmes. Moreover, increasing disposable income, increasing incidences of influenza, introduction of new vaccines, entry of new players, and rising R&D investments are set to further boost the market's growth. Owing to such factors, the Indian influenza market is anticipated to grow at a healthy CAGR during the forecast period (2015-2020).

In the report "IIndian Influenza Market By Product Type (Vaxigrip, Influvac)-Forecast 2020", RNCOS analysts have endeavoured to address the current scenario of Indian influenza industry, factors favouring growth of the market, and the major roadblocks restraining the influenza vaccines market. Additionally, the report includes the study of opportunities, which are available in the Indian influenza market.

Furthermore, the report covers detailed description of the current scenario of the Indian influenza vaccine market, and its future forecast till 2020. Indian Influenza Vaccines market is analyzed in both volumes in doses, and value in US$ for the period from 2015 through to 2020. The report also provides detailed bifurcation of Indian influenza market on the basis of product type, such as Vaxigrip, Influvac, and others. The report also provides the potential market for influenza vaccines. Moreover, the report highlights the mergers and acquisitions that have taken place in the Indian influenza market. Pricing analysis along with the regulatory scenario governing the Indian influenza market has also been mentioned in the report. Furthermore, the report provides the details about the distribution channel for influenza vaccines in the Indian industry.

The latter half of the report provides competitive landscape including the market share of key players, such as Cipla Ltd., Bharat Biotech, Serum Institute of India, Abbott, Lupin Ltd, and others. A brief business overview and financial information about each of these players has been provided in the report, along with the company overviews and financial revenues of the key participants to develop their positions in the global market. The recent development and strength-weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian Influenza market.

 Table of Contents
1. Analyst View
2. Research Methodology
3. Influenza Vaccine - Introduction
4. Market Dynamics
    4.1 Drivers
          4.1.1 Increasing Initiatives for Creating Awareness
          4.1.2 Precipitous Rise in Influenza Cases
          4.1.3 Investments by Organizations
          4.1.4 Increasing Government  Initiatives for Influenza Vaccination Coverage
          4.1.5 Growing Affordability for Expensive Drugs
    4.2 Challenges
          4.2.1 Expensive and Time Consuming Manufacturing Processes
          4.2.2 Lack of  Proper Infrastructure
    4.3 Opportunities
          4.3.1 Surging Demand by Ageing Population
          4.3.2 Explosive Population Growth
          4.3.3 Innovative Technologies Boosting Influenza Vaccine Production
    4.4 Trends
          4.4.1 Collaboration & Consolidation
          4.4.2 Upsurge in the Number of Product Launches
5. Indian Influenza Market Outlook 2020
    5.1 Value Market
    5.2 Unit Volume Market
    5.3 Indian Influenza Market by Product
         5.3.1 Vaxigrip
         5.3.2 Influvac
         5.3.3 Others
    5.4 Potential Market
6. Market Insights
    6.1 Pricing Analysis
    6.2 Distribution and Supply Chain
    6.3 Cold Storage Overview
7. Competitive Landscape
    7.1 Share of Major Players
8. Key Players Analysis
    8.1 Cipla Limited
    8.2 Bharat Biotech
    8.3 Panacea Biotec Limited
    8.4 Zydus Cadilla
    8.5 Lupin Ltd.
    8.6 Abbott Laboratories
    8.7 GlaxoSmithKline Plc (GSK)
    8.8 Sanofi
    8.9 CPL Biologicals Pvt. Ltd.
    8.10 Serum Institute of India
    8.11 Seqirus - A CSL Company

List of Tables:

Table 5-1: India - Import Data of Vaxigrip (Million Doses), 2014-2016
Table 5-2: India - Import Data of Influvac (Million Doses), 2014-2016
Table 5-3: India - Import Data of Agrippal & Fluarix (Million Doses), 2014-2016
Table 5-4: Potential Patients for Influenza (2015 & 2020)
Table 6-1: India - Major Influenza Vaccines Price/Unit (US$)
Table 6-2: India - Major Influenza Vaccines Import Price/Unit (US$)
Table 6-3: India - Number of Government Cold Chain Stores
Table 8-1: Cipla Limited - Financials (Million US$), FY2014-FY2016
Table 8-2: Cipla Limited - Commercialized Influenza Vaccine
Table 8-3: Bharat Biotech - Commercialized Influenza Vaccine
Table 8-4: Panacea Biotec Limited - Financials (Million US$), FY2014-FY2016
Table 8-5: Panacea Biotec Limited - Commercialized Influenza Vaccine
Table 8-6: Zydus Cadila - Financials (Million US$), FY2014-FY2016
Table 8-7: Zydus Cadila - Commercialized Influenza Vaccine
Table 8-8: Lupin Limited - Revenues by Business Segment (Billion US$), 2016
Table 8-9: Abbott Laboratories - Financials (Billion US$), 2013-2015
Table 8-10: Abbott India Limited. - Commercialized Influenza Vaccine
Table 8-11: GlaxoSmithKline Plc - Key Financials (Million US$), 2013-2015
Table 8-12: GlaxoSmithKline Plc - Commercialized Influenza Vaccine
Table 8-13: Sanofi - Key Financials (Million US$), 2013-2015
Table 8-14: Sanofi Pasteur - Commercialized Influenza Vaccine
Table 8-15: CPL Biologicals Pvt. Ltd. - Commercialized Influenza Vaccine
Table 8-16: Serum Institute of India Pvt. Ltd. - Commercialized Influenza Vaccine
Table 8-17: CSL Ltd. - Key Financials (Million US$), 2014-2016
Table 8-18: Seqirus - Commercialized Influenza Vaccine